Early and late myasthenia gravis
Year: 2016, volume 12 Issue: №2 Pages: 287-292
Heading: Neurology Article type: Original article
Authors: Romanova T.V., Poverennova I.E.
Organization: Samara State Medical University
Heading: Neurology Article type: Original article
Authors: Romanova T.V., Poverennova I.E.
Organization: Samara State Medical University
Summary:
The aim: the hypothesis testing of the existence of two different groups of patients with different age at disease onset in a large population of patients with methods multidimensional constellation. Materials and Methods. Analysis of 444 patients enrolled in the register of patients with myasthenia in the Samara region. The duration of disease was more than 1 year. Statistical results of the study was carried out using a multi-dimensional grouping by cluster analysis Checking the quality of the classification was carried out using discriminant analysis. Results. Transient age between the two groups was defined as 40 years. The most important criteria of distinction patients group was sex of the patient and the presence of thymic hyperplasia. Conclusion. These clinical and immunologic patterns of early-onset and late-onset myasthenia gravis can serve as a basis of formation flow forecast model of myasthenia gravis and to create an algorithm of patient management.
Keywords: age of manifestation, clinical and immunological pattern, myasthenia gravis, thymic hyperplasia
Bibliography:
1. Lantsova V.B., Sepp EK. The antigenic targets in myasthenia. Immunology and Allergology 2004; 5 (1): 196-198
2. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8 (5): 475-490
3. Vincent A. Autoantibodies at the neuromuscular junction — link to the central nervous system. Re Neurol (Paris) 2014; 170 (10): 584-586
4. Ponomareva E.N. Myasthenia gravis: clinic, pathogenesis, differential diagnosis, management tactics. Minsk: MET, 2002; 175 p.
5. Romanova T.V. Epidemiological study of myasthenia gravis in the Samara region. Saratov Journal of Medical Scientific Research 2012; 1 (08): 91-95
6. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: clinical, immunological and therapeutic advances. Acta Neurol Scand 2005; 111 (2): 134-141
7. Sanadze A.G. Myasthenia gravis and myasthenic syndromes. Moscow: Litterra, 2012; 255 p.\8
8. Sanadze A.G. Myasthenia gravis. In: Autoimmune diseases in neurology: Clinical Guide. Moscow: ROOI Zdorovie cheloveka, 2014; p. 101-128
9. Akaishi Т, Yamaguchi Т, Suzuki Y, et al. In sightsinto the classification of myasthenia gravis. PLoS One 2014; 9 (9):
e106757. doi: 10.1371 /journal, pone. 0106757 (5 September 2014)
10. Barbaud A, Carlander B, Pagns M. Late onset forms of myasthenia gravis. Comparison with early-onset myasthenia gravis. Rev Neurol 2006; 162 (10): 990-996
11. Chan KH, Cheung RT, Mak W, et al. Nonthymoma early-onset- and late-onset-generalized myasthenia gravis: a retrospective hospital-based study. Clin Neurol Neurosurg 2007; 109 (8): 686-691.
| Attachment | Size |
|---|---|
| 2016_02-1_287-292.pdf | 658.98 KB |
Русский
English